Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099184 · ClinicalTrials.gov registry record · Phase 2
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A Phase 2 study of Diabetic Macular Edema, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT06099184: Completed Phase 2 study of Diabetic Macular Edema, sponsored by EyePoint Pharmaceuticals.
NCT06099184 is a Phase 2 study of Diabetic Macular Edema that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 27 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06099184, a Phase 2 study of Diabetic Macular Edema, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Primary Outcome
Timing of supplemental injection
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept 2Mg/0.05Ml Inj,Oph
Study Locations (6)
Arizona
- EyePoint Investigative Site - Phoenix
Illinois
- EyePoint Investigative Site - Lemont
Maryland
- EyePoint Investigative Site - Hagerstown
Nevada
- EyePoint Investigative Site - Reno
Pennsylvania
- EyePoint Investigative Site - Erie
Virginia
- EyePoint Investigative Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 2 |
What the finished NCT06099184 record still lists
NCT06099184 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which EYP-1901 is the first listed.
NCT06099184 lists 6 locations in 6 states (Arizona, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT06099184 about?
NCT06099184 is a clinical study titled "Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)". A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
What is the current status of trial NCT06099184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2024-01-15. Estimated completion is 2024-10-24.
What conditions does trial NCT06099184 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06099184?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept 2Mg/0.05Ml Inj,Oph (DRUG).
Who is sponsoring clinical trial NCT06099184?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06099184 being conducted?
This trial has 6 study locations across Arizona, Illinois, Maryland, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06099184's enrollment target sits among peer trials
27 48th of 63 higher than 16 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI